- Home
- INVA vs OCUL Comparison
INVA vs OCUL Comparison
Compare INVA & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | OCUL |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | INVA | OCUL |
|---|---|---|
| Price | $21.27 | $10.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $32.80 | $23.56 |
| AVG Volume (30 Days) | 608.5K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $217,217,000.00 | $1,990,000.00 |
| Revenue This Year | $8.95 | $7.93 |
| Revenue Next Year | $12.65 | $96.07 |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | ★ 62.63 | 3.48 |
| 52 Week Low | $16.52 | $6.23 |
| 52 Week High | $25.15 | $16.44 |
Technical Indicators
Market Signals| Indicator | INVA | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 55.22 |
| Support Level | $20.32 | $7.96 |
| Resistance Level | $21.91 | $10.78 |
| Average True Range (ATR) | 0.33 | 0.50 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 56.09 | 28.26 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.